Skip to main content
. 2023 Feb 16;72(7):2045–2056. doi: 10.1007/s00262-023-03386-7

Table 2.

Treatment-related adverse events in the patients

All treated patients (n = 6)
Grade 1–2 Grade 3–4
Constitutional
Injection-site reaction 6 (100%) 0
Flu-like symptoms 0 0
Fever 0 0
Fatigue 0 0
Chills 0 0
Dizziness 0 0
Gastrointestinal
Nausea 0 0
Constipation 0 0
Vomiting 0 0
Diarrhea 0 0
Dry mouth 0 0
Respiratory
Cough 0 0
Dyspnea 0 0
Laboratory
Anemia 0 0
Neutropenia 0 0
Other
Rash 1(16.7%) 0
Headache 1(16.7%) 0

*Including all patients who received at least one dose of trial treatment